Veracyte Q2 revenue rises on Decipher and Afirma test sales

Veracyte

30/07/2026 21:23

Overview
Cancer diagnostics firm's Q2 revenue rose 15% yr/yr, beating analyst expectations
Adjusted EPS for Q2 increased from prior year, supported by higher testing revenue and margins
Company launched two new cancer tests and raised 2026 revenue guidance

Outlook
Veracyte raises 2026 total revenue guidance to $590 mln-$596 mln, up from $582 mln-$592 mln
Company raises 2026 testing revenue guidance to $576 mln-$582 mln, up from $570 mln-$580 mln
Veracyte continues to expect adjusted EBITDA margin to be greater than 26%

Result Drivers
TESTING GROWTH - Revenue growth was driven by Decipher and Afirma test sales, which rose 20% and 18% yr/yr, respectively
NEW PRODUCT LAUNCHES - Co launched Prosigna Breast Test and TrueMRD Monitoring Test for MIBC during the quarter
HIGHER TESTING VOLUMES - Total testing volume rose 14% yr/yr, led by Decipher and Afirma

Company press release: ID:nGNX6XSMBF

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$150.30 mln
$144.55 mln (11 Analysts)
Q2 Net Income
 
$25.50 mln
 
Q2 Gross Margin
 
72.20%
 
Q2 Adjusted Operating Expenses
 
$70 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Veracyte Inc is $56.00, about 0.5% above its July 29 closing price of $55.71
The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 33 three months ago

Reuters Recommended Reads
July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook
July 29 - Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates
July 28 - US FDA staff cast doubt on Replimune cancer drug's benefit; shares slide

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)